Cuarto Consenso Nacional de Cáncer de Ovario

Gallardo‐Rincón, Dolores; Ruvalcaba-Limón, Eva; Silva-García, Araceli; Aranda-Flores, Carlos; Quijano-Castro, Odilón Félix; Montalvo-Esquivel, Gonzalo; Pérez-Quintanilla, Milagros; Bahena-González, Antonio; Alamilla-García, Gabriela; Espinosa-Romero, Raquel; Álvarez-Gómez, Rosa María; Carrillo-Garibaldi, Óscar Joel; León, David Cantú de; Herbert-Núñez, Guillermo Sidney; Hinojosa-García, Luz María; Morales-Palomares, Miguel Ángel; Ochoa‐Carrillo, Francisco Javier; Oñate‐Ocaña, Luis F.; Oliva-Posada, Juan Carlos; Salcedo-Hernández, Rosa María; Maffuz‐Aziz, Antonio; Isla‐Ortiz, David; Medina-Castro, Juan Manuel; Güemes-Meza, Agustín; Rodríguez-Trejo, Amelia; Avila-Monteverde, Enrique; Tabarez-Ortiz, Adán Raúl; Salcedo‐Hernández, Rosa A.; Real-Ordoñez, Sarish Del; Garnica-Jaliffe, Georgina; Hernández-Luis, Gisela; Morán-Mendoza, Andrés; Rivera, Samuel; Cortés-Esteban, Patricia; Villalobos-Valencia, Ricardo; Enríquez-Aceves, Isabel; Green-Renner, Dan; Morales-Vásquez, Flavia; Durazo-Bustamante, F.; Ruiz-García, Érika; Avitia, Miguel Ángel Álvarez; Bañuelos-Flores, Joel; Gómez-García, Eva

doi:10.24875/j.gamo.m18000155

Cited by 2 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a definite need to define and identify high-risk populations for the development of OC and screen these patients with transvaginal ultrasound and serum CA125 determination every six months [38].…”

Section: New Screening Toolsmentioning

confidence: 99%

Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature

Elorriaga

Neyro

Mieza

et al. 2021

JPM

View full text Add to dashboard Cite

Background: Ovarian cancer has a low incidence, but high mortality due to a habitual diagnosis in advanced cancer stages. Currently, used biomarkers have good sensitivity, but low specificity. Aim: To determine the usefulness of the biomarkers and algorithms used up to now in the screening, diagnosis, response to treatments and identification of recurrence in patients with ovarian masses. Methodology: Systematic search of publications in English in the Medline-PubMed database with the terms: “biomarkers”, “tumour”, “tumour biomarkers”, “marker”, “tumour marker”, “ovarian cancer”, “ovarian”, “Neoplasms”, “cancer”, CA-125 Antigen; Human Epididymis-specific Protein E4; Risk of Malignancy Index (RMI); Risk of Ovarian Malignancy Algorithm (ROMA); Ovarian Neoplasms. Original articles, clinical trials, reviews, systematic reviews and meta-analyses, published between January 2000 and November 2020, were selected to determine the usefulness (among others) of CA 125 and HE4 antigen in ovarian cancer. Results: Finally, 39 transcendental publications were selected to write this article to determine the usefulness of tumour markers and algorithms in ovarian cancer. Conclusions: The usefulness of the tumour markers antigen CA125 and antigen HE4 individually or as a basis for decision-making algorithms has low specificity; however, there is little evidence that confirms their usefulness as markers in ovarian cancer screening.

show abstract

Section: New Screening Toolsmentioning

confidence: 99%

Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature

Elorriaga

Neyro

Mieza

et al. 2021

JPM

View full text Add to dashboard Cite

show abstract

“…In our country, Mexico, more than 4,000 new cases were registered and it is the fourth most common cause of death in women, its average diagnosis age being between 50 and 70 years, unfortunately in locally advanced stages [10]. Fortunately, 80% of cases responded to primary treatment, although they have a high relapse rate in 60–70% of cases as a result of a lack of suitable research methods, favoured by the low symptomatology, and a lack of early-stage screening techniques, which hinder timely diagnosis of the only curable stage of ovarian cancer (the early stage) [6]. In the presence of any pelvic tumour, recommendations have been published to understand the risk of malignancy index for ovarian tumour (RMI I), described by Jacobs in 1990.…”

Section: Developmentmentioning

confidence: 99%

“…Among the related factors, these are some of them: tumour heterogeneity, size of the studied population, and the different sample processing techniques [6]. …”

Section: Histopathological and Molecular Diagnosismentioning

confidence: 99%

“…It is the most common malignancy after breast cancer in women over 40 years of age, particularly in developed countries, and in Mexico it stands in fourth place among the deaths caused by gynaecological tumours [6]. Epithelial ovarian cancer occurs in about 90% of cases, and only 10% originate from germ cells, from sex cords, and from ovarian stroma cells.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

ecancermedicalscience

View full text Add to dashboard Cite

Ovarian cancer is a disease laden with paradigms, and it is a serious health problem. It is important to know its natural history, as it is multifactorial in origin, and also to understand its behaviour given its risk factors which can lead to death from metastasis in patients. It continues to be a challenge for oncologists. An analytical literature review was performed to update the latest concepts of its origin, evolution, risk factors, pre-clinical horizon, and its clinical manifestations; until the death of the patient.

show abstract

Cuarto Consenso Nacional de Cáncer de Ovario

Abstract: Impreso en papel totalmente libre de cloro Edición impresa en México

Cited by 2 publications

References 18 publications

Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature

Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature

ecancermedicalscience

Contact Info

Product

Resources

About